Clinical Research Directory
Browse clinical research sites, groups, and studies.
MSA-01 in Multiple System Atrophy
Sponsor: Tokyo University
Summary
The purpose of this study is to evaluate whether MSA-01 slows the progression of multiple system atrophy (MSA) and to assess its safety. The primary question is: • Does MSA-01 slow the progression of motor impairment as measured by UMSARS Part 2 score? Participants will be randomly assigned to receive MSA-01 or placebo for 12 months. They will attend regular clinic visits for safety and efficacy assessments and record their medication use and any side effects in a diary.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study of MSA-01 in Patients With Multiple System Atrophy
Key Details
Gender
All
Age Range
30 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2026-02-09
Completion Date
2028-03-31
Last Updated
2026-03-04
Healthy Volunteers
No
Conditions
Interventions
MSA-01
Ubiquinol
Placebo
Placebo
Locations (12)
Nagoya University Hospital
Nagoya, Aichi-ken, Japan
Chiba University Hospital
Chiba, Chiba, Japan
Kyushu University Hospital
Fukuoka, Fukuoka, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Kagoshima University Hospital
Kagoshima, Kagoshima-ken, Japan
Kyoto University Hospital
Kyoto, Kyoto, Japan
Okayama University Hospital
Okayama, Okayama-ken, Japan
NHO Higashisaitama National Hospital
Hasuda, Saitama, Japan
Institute of Science Tokyo Hospital
Bunkyō-Ku, Tokyo, Japan
The University of Tokyo Hospital
Bunkyō-Ku, Tokyo, Japan
National Center Hospital, National Center of Neurology and Psychiatry
Kodaira, Tokyo, Japan
Tottori University Hospital
Yonago, Tottori, Japan